Clinical Trial Update: A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

A Phase 2 dose-confirmation study of oral clofarabine in adults previously treated for myelodysplastic syndromes (MDS) has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Clofarabine (clofarabine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia (AML) | Phase 2 | Status: COMPLETED | Results posted: 2021-11-02